Document is current

Article History

Received: 25 March 2025

Accepted: 11 June 2025

First Online: 18 July 2025

Declarations

:

: This work does not contain any studies on human or animal subjects performed by any of the authors.

: Not applicable to this work. The PROSPERO study protocol was submitted to and approved by the Ethics Committee of each participating center.

: CC and CR are Novartis employees. VDS: advisory board for AOP Health, Bristol Myers Squibb, Glaxo Smith Kline, Grifols, Novartis, SOBI, Takeda; speaker fees from Abbvie, Alexion, Amgen, Bristol Myers Squibb, Grifols, Novartis, Novo Nordisk, Sanofi, Takeda; research grant from Alexion. GB: Advisory board for Novartis, GSK; speakers bureau of Novartis, BMS, Janssen, Menarini, GSK. MB: honoraria by Novartis, Incyte, Pfizer, BMS, AOP, Abbvie, GSK. AI: speaker honoraria from AOP Health and Novartis. MM: consultant for AstraZeneca, Roche, Novartis, Gilead, MSD. E. Masselli: consultancy and honoraria from Novartis, BMS and GSK. F. Palandri: speakers bureau and advisory board of Novartis, BMS, AOP, Sierra Oncology, Incyte, Telios, Abbvie, Constellation-Morphosys, Sobi and GSK. F. Passamonti: honoraria during the last two years for lectures from Novartis, Bristol-Myers Squibb, Abbvie, GSK, AOP Orphan, Jazz and for advisory boards from Novartis, Bristol-Myers Squibb/Celgene, GSK, Abbvie, Keros, Sumitomo. NP: advisory board for Novartis, GSK; consultant for AOP. The other authors have nothing to declare. F. Palandri and M. Breccia serve as editors for the Annals of Hematology journal.